Final Results From the ASCENT Trial in Metastatic Triple-Negative Breast Cancer
Posted: 05/01/2024 | By: Sarah Campen, PharmD

The phase III ASCENT study compared the efficacy of sacituzumab govitecan-hziy to single-agent chemotherapy (physician’s choice) in patients with metastatic triple-negative breast cancer. Final results from the trial were recently published by Bardia et al in the Journal of Clinical Oncology.

Question 1 of 5

What is the surface antigen targeted by sacituzumab govitecan-hziy?

Choose 1